Design, synthesis and antimicrobial activities of some new quinoline derivatives carrying 1,2,3-triazole moiety
| dc.contributor.author | Thomas, K.D. | |
| dc.contributor.author | Vasudeva Adhikari, A.V. | |
| dc.contributor.author | Shetty, N.S. | |
| dc.date.accessioned | 2026-02-05T09:36:14Z | |
| dc.date.issued | 2010 | |
| dc.description.abstract | A new series of [1-(6-methoxy-2-methylquinolin-4-yl)-1H-1,2,3-triazol-4-yl] methanamine derivatives were synthesized starting from 4-methoxyaniline through multi-step reactions. The title compounds 5a-y were prepared by treating the azide intermediate 4 with propargyl bromide and different alkyl/heterocyclic amines in a sequential three component synthesis. All the new compounds were characterized by spectral and elemental analyses. The newly synthesized final compounds were evaluated for their in vitro antibacterial and antifungal activities against pathogenic strains. The preliminary screening results indicated that most of the compounds demonstrated moderate to very good antibacterial and antifungal activities, comparable to the first-line drugs. Twenty five new derivatives of [1-(6-methoxy-2-methylquinolin-4-yl)-1H-1,2,3- triazol-4-yl] methanamine have been synthesized and the most effective compounds have MIC of 6.25 ?g/mL, which are in comparable with present antibiotics. © 2010 Elsevier Masson SAS. All rights reserved. | |
| dc.identifier.citation | European Journal of Medicinal Chemistry, 2010, 45, 9, pp. 3803-3810 | |
| dc.identifier.issn | 2235234 | |
| dc.identifier.uri | https://doi.org/10.1016/j.ejmech.2010.05.030 | |
| dc.identifier.uri | https://idr.nitk.ac.in/handle/123456789/27422 | |
| dc.subject | 1 [1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl] n,n dimethyl methanamine | |
| dc.subject | 1 [4 [[1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl]methyl]piperazin 1 yl]ethanone | |
| dc.subject | 4 [4 [(4 cyclohexylpiperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl] 6 methoxy 2 methylquinoline | |
| dc.subject | 4 [4 [(4 ethylpiperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl] 6 methoxy 2 methyl quinoline | |
| dc.subject | 4 [4 [(4 ethylpiperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl] 6 methoxy 2 methylquinoline | |
| dc.subject | 4 [4 [(4 isopropylpiperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl] 6 methoxy 2 methylquinoline | |
| dc.subject | 4 [4 [[4 (2 fluorophenyl)piperazin 1 yl]methyl] (1h) 1,2,3 triazol 1 yl] 6 methoxy 2 methylquinoline | |
| dc.subject | 4 [4 [[4 (4 fluorophenyl)piperazin 1 yl]methyl] (1h) 1,2,3 triazol 1 yl] 6 methoxy 2 methylquinoline | |
| dc.subject | 6 methoxy 2 methyl 4 [4 [(4 methylpiperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl]quinoline | |
| dc.subject | 6 methoxy 2 methyl 4 [4 [(4 morpholinopiperidin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl]quinoline | |
| dc.subject | 6 methoxy 2 methyl 4 [4 [(4 p tolylpiperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl]quinoline | |
| dc.subject | 6 methoxy 2 methyl 4 [4 [(4 phenylpiperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl]quinoline | |
| dc.subject | 6 methoxy 2 methyl 4 [4 [(piperidin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl]quinoline | |
| dc.subject | 6 methoxy 2 methyl 4 [4 [(pyrrolidin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl]quinoline | |
| dc.subject | 6 methoxy 4 [4 [(4 (4 methoxyphenyl) piperazin 1 yl)methyl] (1h) 1,2,3 triazol 1 yl] 2 methylquinoline | |
| dc.subject | 6 methoxy 4 [4 [[4 (4 methoxy 2 methylphenyl)piperazin 1 yl]methyl] (1h) 1,2,3 triazol 1 yl] 2 methylquinoline | |
| dc.subject | ciclopiroxolamine | |
| dc.subject | ciprofloxacin | |
| dc.subject | n [1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl]methyl cyclopropanamine | |
| dc.subject | n [1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl]methylamine | |
| dc.subject | n [[1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl]methyl]butan 2 amine | |
| dc.subject | n [[1 (6 methoxy 2 methylquinolin 4 yl) (1h) imidazol 4 yl]methyl]cyclohexanamine | |
| dc.subject | n [[1 (6 methoxy 2 methylquinolin 4 yl) (1h) imidazol 4 yl]methyl]cyclopentanamine | |
| dc.subject | n ethyl n [[1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl]methyl]ethanamine | |
| dc.subject | n1 [[1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl]methyl] n1,n2,n2 trimethylethane 1,2 diamine | |
| dc.subject | n1 [[1 (6 methoxy 2 methylquinolin 4 yl) (1h) 1,2,3 triazol 4 yl]methyl] n3,n3 diimethylpropane 1,3 diamine | |
| dc.subject | quinoline derivative | |
| dc.subject | unclassified drug | |
| dc.subject | antifungal activity | |
| dc.subject | antimicrobial activity | |
| dc.subject | article | |
| dc.subject | Aspergillus flavus | |
| dc.subject | Aspergillus fumigatus | |
| dc.subject | bacterial strain | |
| dc.subject | bacterium culture | |
| dc.subject | Candida albicans | |
| dc.subject | controlled study | |
| dc.subject | drug design | |
| dc.subject | drug structure | |
| dc.subject | drug synthesis | |
| dc.subject | Escherichia coli | |
| dc.subject | fungal strain | |
| dc.subject | infrared spectroscopy | |
| dc.subject | Klebsiella pneumoniae | |
| dc.subject | minimum inhibitory concentration | |
| dc.subject | nonhuman | |
| dc.subject | nuclear magnetic resonance spectroscopy | |
| dc.subject | Penicillium marneffei | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.subject | Staphylococcus aureus | |
| dc.subject | Streptococcus pyogenes | |
| dc.subject | Trichophyton mentagrophytes | |
| dc.subject | Amines | |
| dc.subject | Aniline Compounds | |
| dc.subject | Anti-Infective Agents | |
| dc.subject | Bacteria | |
| dc.subject | Drug Design | |
| dc.subject | Fungi | |
| dc.subject | Microbial Sensitivity Tests | |
| dc.subject | Quinolines | |
| dc.subject | Triazoles | |
| dc.title | Design, synthesis and antimicrobial activities of some new quinoline derivatives carrying 1,2,3-triazole moiety |
